Developed by Eli Lilly · from $45 here
What it is
A lab-made peptide that switches on two receptors, GLP-1 and GIP. It carries a fatty acid chain so it stays in circulation longer. The development code was LY3298176.
What has been studied
Described by Eli Lilly scientists in 2018, tested in cells, then mice, then a first study in people [5]. It is now the active ingredient in approved prescription medicines.
Developed by Eli Lilly · from $45 here
What it is
The same idea taken one receptor further: GLP-1, GIP and glucagon. That makes it a triple agonist. The development code was LY3437943.
What has been studied
Described in 2022. In cells it switched on the glucagon and GLP-1 receptors about equally and the GIP receptor more strongly [6]. Still in clinical development. There is a full comparison with tirzepatide.
Developed by Novo Nordisk · from $50 here
What it is
A lab-made version of amylin, the pancreas hormone. Natural amylin tends to clump into fibres, which makes it hard to turn into a stable compound. Cagrilintide was built with a fatty acid chain to be stable and long-lasting.
What has been studied
Novo Nordisk chemists described how they got there in 2021 [7]. A 2025 Monash University study pictured it sitting in its receptors [8], and a 2026 University of Copenhagen study mapped more than 530,000 brainstem cells in rats, mice and macaques to see which ones respond to it [9].
Developed by Eli Lilly · from $65 here
What it is
Eli Lilly's lab-made amylin, development code LY3841136. It favours one amylin receptor subtype over its close relatives.
What has been studied
In cells it preferred the amylin 1 receptor over the calcitonin receptor and the amylin 3 receptor. The team then worked in rats and monkeys and ran a first study in healthy volunteers [10]. One of the rat experiments compared it directly with cagrilintide.